<ul><li>Beckley Psytech's investor, Noetic Fund, is seeking to invest up to $20 million in the biotech startup at a $200 million valuation.</li><li>Beckley Psytech is developing a psychedelic-based nasal spray to treat depression and alcohol use disorder.</li><li>The raise would value Beckley Psytech at $220 million after the fundraise, with the company having raised $143 million to date.</li><li>The startup aims to publish phase 2b clinical trial data and potentially go public or pursue a strategic M&A deal within the next 12 months.</li></ul>

Beckley Psytech's investors want to put more money into the psychedelics company at a $200M valuation

Discover more